RESUMEN
BACKGROUND: Bullous Pemphigoid (BP) is the most common autoimmune blistering disease. Most patients are elderly and associate multiple comorbidities. Topical and systemic corticosteroids are considered as the first-line treatment for BP and immunosuppressors are used as steroid-sparing treatments but both have side effects and contraindications which are even more common in this elderly population. New treatments targeting interleukins and receptors related to BP pathogenesis have been proposed to decrease this side effects while achieving equal or better effectiveness response rates.Omalizumab is a monoclonal antibody that targets IgE that has been proposed for the treatment of BP due to the evidence that IgE autoantibodies play an essential role in BP pathogenesis. OBJECTIVES AND METHODOLOGY: To assess the efficacy and security of Omalizumab for the treatment of BP, we carried out a multicenter, retrospective, observational study including patients diagnosed of BP who received omalizumab for at least 3 months from 15 tertiary hospitals in Spain. IgE levels prior to treatment was measured and we evaluate the possible correlation with clinical response. We excluded patients treated with Omalizumab for less than 3 months as we consider this duration is insufficient for a comprehensive assessment of its efficacy. To evaluate the effectiveness of the treatment we used the percentage of BSA improvement. RESULTS: We included 36 patients. The vast majority associate multiple comorbidities and all patients had used other systemic therapies apart from corticoids before Omalizumab.83% experienced some kind of treatment response and 42% of all patient treated achieved complete response.We did not find any correlation between higher levels and a better response (p=0,1791).All patients tolerated Omalizumab without reported side-effects. CONCLUSIONS: Omalizumab is a good therapeutic alternative for BP as it obtained clinical response in most patients and nearly half of the cases achieving complete response. It showed no side effects which is crucial in elderly patients suffering from BP.
RESUMEN
Diaper dermatitis is a common dermatosis that usually responds to adequate hygiene and topical treatment, but can be a therapeutic challenge. Continuous exposure to feces and urine can cause extensive erosions and pain. The use of hydrocolloid dressings may be helpful in keeping the skin isolated from stool and urine, reducing pain, and enabling skin lesions to heal. We explain an easy technique, utilizing stoma powder and a hydrocolloid dressing, for parents to apply at home.
Asunto(s)
Vendas Hidrocoloidales , Dermatitis del Pañal , Humanos , Vendas Hidrocoloidales/efectos adversos , Dermatitis del Pañal/terapia , Dermatitis del Pañal/etiología , Piel , Cicatrización de Heridas , Administración TópicaAsunto(s)
Acantólisis/diagnóstico , COVID-19/diagnóstico , Ictiosis/diagnóstico , SARS-CoV-2/aislamiento & purificación , Acantólisis/sangre , Acantólisis/inmunología , Acantólisis/patología , Biopsia , COVID-19/complicaciones , COVID-19/inmunología , COVID-19/virología , Prueba Serológica para COVID-19 , Dermoscopía , Diagnóstico Diferencial , Exantema , Humanos , Ictiosis/sangre , Ictiosis/inmunología , Ictiosis/patología , Masculino , Persona de Mediana Edad , SARS-CoV-2/inmunología , SARS-CoV-2/patogenicidad , Piel/diagnóstico por imagen , Piel/patologíaRESUMEN
Congenital hemangiomas (CH) are benign vascular tumors that are present at birth and do not stain for the marker Glut-1. Herein, we describe five cases of CH with atypical presentations: 3 with late growth, 1 with slow involution, and 1 that partially involuted rapidly then manifested late growth.
Asunto(s)
Hemangioma , Neoplasias Cutáneas , Neoplasias Vasculares , Colorantes , Hemangioma/diagnóstico , Humanos , Lactante , Recién Nacido , Fenotipo , Neoplasias Cutáneas/diagnósticoAsunto(s)
Queilitis/diagnóstico , Trastornos por Fotosensibilidad/diagnóstico , Prurito/diagnóstico , Enfermedades Cutáneas Genéticas/diagnóstico , Adulto , Biopsia , Queilitis/etiología , Queilitis/terapia , Femenino , Humanos , Labio , Trastornos por Fotosensibilidad/etiología , Trastornos por Fotosensibilidad/patología , Trastornos por Fotosensibilidad/terapia , Prurito/etiología , Prurito/patología , Prurito/terapia , Piel/patología , Piel/efectos de la radiación , Enfermedades Cutáneas Genéticas/etiología , Enfermedades Cutáneas Genéticas/patología , Enfermedades Cutáneas Genéticas/terapia , Pruebas Cutáneas , Protectores Solares/administración & dosificación , Resultado del Tratamiento , Rayos Ultravioleta/efectos adversos , Terapia Ultravioleta/métodosAsunto(s)
Argiria/patología , Argiria/etiología , Dermoscopía , Femenino , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Necrosis Grasa/patología , Grasa Subcutánea/patología , Humanos , Recién Nacido , MasculinoAsunto(s)
Humanos , Masculino , Recién Nacido , Grasa Subcutánea/patología , Necrosis Grasa/patologíaRESUMEN
Mycosis Fungoides is the most common cutaneous T-cell lymphoma however, it is rare in children. We present the case of a Folliculotropic Mycosis Fungoides in a 13-year-old boy which initially presented as a plaque on his face and was treated with local PUVA therapy. Afterwards the lesions spread so the treatment was changed to systemic PUVA with good response. Although the experience in the treatment of Mycosis Fungoides in pediatric patients is limited, PUVA therapy seems to be an effective and safe option.